ArticleCell death discovery2025
NCOA7 inhibits renal cancer progression by inducing autophagy and lipid metabolism through V-ATPase interaction.
Article in Cell death discovery, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Integrated experimental and network pharmacology analyses reveal inhibitory effects of albiflorin on renal cell carcinoma cells.Naunyn-Schmiedeberg's archives of pharmacology · 2026Article
- KIF7 promotes the proliferation of clear cell renal cell carcinoma by activating the WNT/β-catenin signaling pathway.Clinical and experimental medicine · 2026Article
- Necrosis by sodium overload: a potential mechanism for renal diseases associated with mitochondrial dysfunction.Cell death discovery · 2026Article
- NCOA7 promotes OSCC progression by inhibiting ROS-regulated ferroptosis.Cellular and molecular life sciences : CMLS · 2026Article
Corrections and comments
- Erratum issued
Authors and funding
8 authors.
Funding
Abstract
Clear cell renal cell carcinoma is the predominant pathological subtype of renal cell carcinoma, characterized by abnormal lipid metabolism. This study aimed to investigate the role of nuclear receptor co-activator 7 (NCOA7)-mediated autophagy in lipid metabolism in renal cancer and its effects on renal cancer progression. To this end, bioinformatic analysis was performed to analyze the prognostic significance of NCOA7 in renal cancer. Immunohistochemical staining and protein blotting were used to assess NCOA7 expression levels in clinical samples. Various assays, including scratch, Transwell, colony formation, and Oil Red O staining, were used to observe the effects of NCOA7 on the biological behavior and lipid metabolism of renal cancer cells. The interaction between NCOA7 and V-ATPase was investigated using immunoprecipitation. Additionally, NCOA7 expression was modulated in renal cancer cell lines transfected with LC3 dual-fluorescent virus to study its effects on lysosomal function, autophagy, and lipid metabolism. The effects of NCOA7 expression levels on subcutaneous tumors were investigated using a nude mouse xenograft model. Bioinformatics analysis showed that NCOA7 was expressed at low levels in renal cancer tissues and independently associated with the prognosis in patients with renal cancer. In vitro experiments showed that high NCOA7 expression inhibited the proliferation, migration, and invasion of renal cancer cells. NCOA7 promoted the fusion of lysosomes with autophagosomes through its interaction with V-ATPase. High expression of NCOA7 enhanced autophagy and lipid metabolism and inhibited the growth of renal cancer cells. In vivo experiments showed that high NCOA7 expression inhibited the growth of subcutaneous tumors in nude mice. Our study demonstrates that NCOA7 promotes autophagy and reduces lipid accumulation by binding to V-ATPase and ultimately inhibits the progression of renal cancer. These findings suggest that NCOA7 might be a potential target for drug intervention in clear cell renal carcinoma. The schematic illustrates that NCOA7 upregulation interacts with V-ATPase to promote autophagosome-lysosome fusion, enhance autophagic degradation of lipid droplets, and thereby suppress proliferation, migration, and invasion of kidney cancer cells. Image created with BioRender.com, with permission.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.